
Key Takeaways:
- Lepu Biopharma will incur more operational costs as it builds up its production capacity and sales and marketing teams to commercialize its first approved product
- The company’s stock surged after it said it would list on Shanghai’s STAR Market and be included in the Shenzhen-Hong Kong Stock Connect program